Hemolytic anemia primary prevention: Difference between revisions
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) |
||
| Line 13: | Line 13: | ||
*Avoidance of immunotherapeutic drugs | *Avoidance of immunotherapeutic drugs | ||
*Avoidance of unnecessary antibiotics like trimethoprim-sulfamethaxone<ref name="pmid9524723">{{cite journal| author=Thomas HL, Livesey MA| title=Immune-mediated hemolytic anemia associated with trimethoprim-sulphamethoxazole administration in a horse. | journal=Can Vet J | year= 1998 | volume= 39 | issue= 3 | pages= 171-3 | pmid=9524723 | doi= | pmc=1539918 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9524723 }} </ref> | *Avoidance of unnecessary antibiotics like trimethoprim-sulfamethaxone<ref name="pmid9524723">{{cite journal| author=Thomas HL, Livesey MA| title=Immune-mediated hemolytic anemia associated with trimethoprim-sulphamethoxazole administration in a horse. | journal=Can Vet J | year= 1998 | volume= 39 | issue= 3 | pages= 171-3 | pmid=9524723 | doi= | pmc=1539918 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9524723 }} </ref> | ||
*Avoidance of fava beans for patients who have G6PD deficiency | *Avoidance of fava beans for patients who have G6PD deficiency<ref name="pmid4714581">{{cite journal| author=Bottini E| title=Favism: current problems and investigations. | journal=J Med Genet | year= 1973 | volume= 10 | issue= 2 | pages= 154-7 | pmid=4714581 | doi= | pmc=1013006 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4714581 }} </ref> | ||
*Use of bioprothetic cardiac valves over mechanical valves to prevent valve-induced hemolysis | *Use of bioprothetic cardiac valves over mechanical valves to prevent valve-induced hemolysis | ||
Revision as of 04:05, 28 October 2017
|
Hemolytic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemolytic anemia primary prevention On the Web |
|
American Roentgen Ray Society Images of Hemolytic anemia primary prevention |
|
Risk calculators and risk factors for Hemolytic anemia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
There is a small role for preventive measures in hemolytic anemia. Primary prevention focuses on preventing the disease onset before the disease process begins. Avoidance of hemolysis triggers a primary prevention measure.
Primary Prevention
Primary prevention for hemolytic anemia includes avoidance of particular triggers for hemolysis. This includes:
- Avoidance of immunotherapeutic drugs
- Avoidance of unnecessary antibiotics like trimethoprim-sulfamethaxone[1]
- Avoidance of fava beans for patients who have G6PD deficiency[2]
- Use of bioprothetic cardiac valves over mechanical valves to prevent valve-induced hemolysis
References
- ↑ Thomas HL, Livesey MA (1998). "Immune-mediated hemolytic anemia associated with trimethoprim-sulphamethoxazole administration in a horse". Can Vet J. 39 (3): 171–3. PMC 1539918. PMID 9524723.
- ↑ Bottini E (1973). "Favism: current problems and investigations". J Med Genet. 10 (2): 154–7. PMC 1013006. PMID 4714581.